Treating resistant melanoma cells with IGF1R inhibitors restores their BRAFi sensitivity [104,105,106], and a combination of BRAF/MEK inhibitors with IGF1R inhibitors significantly reduces melanoma cell growth in vitro and in vivo [107]. Here, IGF1R is linked to melanoma.